Mereo BioPharma Group plc (MREO)
Nasdaq: MREO · Pharmaceutical Preparations · London · filing with the SEC since 2017
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Mar 19, 2026 | Mar 26, 2025 | Mar 27, 2024 | Mar 28, 2023 | Mar 31, 2022 |
| Revenue | 500 | 0 | 10,000 | 0 | · |
| For lenders | |||||
| Interest and dividend income | 104 | 0 | · | · | · |
| Interest and investment income | 2,173 | 3,041 | 2,131 | 840 | · |
| Research and development | 17,766 | 20,930 | 17,418 | 29,465 | · |
| General and administrative | 23,008 | 26,434 | 18,424 | 26,107 | · |
| Total costs and expenses | 700 | 700 | 700 | 900 | · |
| Operating income | -40,107 | -47,364 | -28,416 | -54,426 | · |
| Interest expense | 255 | 1,370 | 2,881 | 4,175 | · |
| Other income (expense), net | 300 | 0 | -10 | 1,086 | · |
| Income before income taxes | -41,878 | -43,253 | -29,998 | -42,938 | · |
| Income tax expense | 0 | 0 | -532 | -718 | · |
| Net income | -41,878 | -43,253 | -29,466 | -42,220 | · |
| Earnings per share, basic | -0.05 | -0.06 | -0.04 | -0.07 | · |
| Earnings per share, diluted | -0.05 | -0.06 | -0.04 | -0.07 | · |
| Weighted average shares, basic | 797,119,632 | 739,624,264 | 659,453,921 | 603,196,403 | · |
| Weighted average shares, diluted | 797,119,632 | 739,624,264 | 659,453,921 | 603,196,403 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesInterest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding